Protaglandins and the antiarrhythmic effect of preconditioning in the isolated rat heart

  • Michael Arad
  • Tatiana Oxman
  • Ron Leor
  • Babeth Rabinowitz
Part of the Developments in Molecular and Cellular Biochemistry book series (DMCB, volume 18)


Our study evaluated the relationship between the endogenous production of prostacyclin and the antiarrhythmic effect of ischemic preconditioning against ischemic and reperfusion-induced tachyarrhythmia. Langendorff perfused rat hearts underwent 30 min regional ischemia with reperfusion. Preconditioning was induced by a single episode of 5 min ischemia and 15 min reperfusion. Prostaglandin 6-keto F (a stable metabolite of prostacyclin) was determined in the coronary effluent.

In the control group the incidence of tachyarrhythmia was 31% during ischemia and 67% during reperfusion. Preconditioning did not affect ischemic arrhythmias but attenuated arrhythmias a reperfusion (8%, p < 0.01) and was associated with increased release of prostacyclin prior to reperfusion. Aspirin abolished the antiarrhythmic effect of preconditioning against reperfusion tachyarrhythmias. However, no relationship was found between suppression of prostacyclin production and the occurrence of arrhythmia in individual hearts.

Thus, our findings suggest that metabolites of arachidonic acid via the cyclooxygenase pathway are involved in the protective effect of ischemic preconditioning against reperfusion-induced tachyarrhythmias. (Mol Cell Biochem 160/161:249–255, 1996)

Key words

preconditioning arrhythmia prostacyclin aspirin rat 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Berger HJ, Zaret BL, Speroff L, Cohen LS, Wolfson S: Regional cardiac prostaglandin release during myocardial ischemia in anesthetized dogs. Circ Res 38: 566–571, 1976PubMedGoogle Scholar
  2. 2.
    Karmazyn M: Contribution of prostaglandins to reperfusion-induced ventricular failure in isolated rat hearts. Am J Physiol 251: H133–H140, 1986PubMedGoogle Scholar
  3. 3.
    Okada T: Hypoxia-induced change in prostaglandin production and coronary flow in isolated rat heart. J Mol Cell Cardiol 23: 930–948, 1991Google Scholar
  4. 4.
    Rabinowitz B, Arad M, Elazar E, Klein R, Har Zahav Y: Epicardial versus endocardial ‘in mirror’ changes in prostaglandin synthesis after short periods of ischemia and reperfusion. Eicosanoid 5: 163–167, 1992Google Scholar
  5. 5.
    Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124–1136, 1986PubMedCrossRefGoogle Scholar
  6. 6.
    Murry CE, Richard VJ, Reimer KA, Jennings RB: Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 66: 913–931, 1990PubMedGoogle Scholar
  7. 7.
    Lawson CS, Dawney JM: Preconditioning: State of the art of myocardial protection. Cardiovasc Res 27: 542–550, 1993PubMedCrossRefGoogle Scholar
  8. 8.
    Hagar JM, Hale SL, Kloner RA: Effect of preconditioning ischemia on reperfusion arrhythmias after coronary artery occlusion and reperfusion in the rat. Circ Res 68: 61–68, 1991PubMedGoogle Scholar
  9. 9.
    Shiki K, Hearse D: Preconditioning of ischemic myocardium: reperfusion induced arrhythmias. Am J Physiol 253: H147–H1476, 1987Google Scholar
  10. 10.
    Vegh A, Szekeres L, Parratt JR: Protective effects of preconditioning of the ischemic myocardium involve cyclooxygenase products. Cardiovasc Res 24: 1020–1023, 1990PubMedCrossRefGoogle Scholar
  11. 11.
    Vegh A, Szekeres L, Parratt J: Preconditioning of the ischemic myocardium — involvement of the L-arginine nitric oxide pathway Br J Pharmacol 107: 648–652, 1992PubMedGoogle Scholar
  12. 12.
    Li Y, Kloner RA: Cardioprotective effects of ischemic preconditioning are not mediated by prostanoids. Cardiovasc Rei 26: 226–231, 1992CrossRefGoogle Scholar
  13. 13.
    Alexander RW, Kent KM, Pisano JJ, Keiser HR, Cooper T: Regulation of postocclusive hyperemia by spontaneously synthesized prostaglandin in the dog heart. J Clin Invest 55:1174–1181, 1995CrossRefGoogle Scholar
  14. 14.
    Woditsch I, Schror K: Prostacyclin rather than nitric oxide is a tissue protective factor in myocardial ischemia. Am J Physiol 263: H1390–H1396, 1992PubMedGoogle Scholar
  15. 15.
    Coker SJ, Marshall RJ, Parratt JR, Zeitlin IJ: Does the local myocardial release of prostaglandin E2 or F2 contribute to the early consequences of acute myocardial ischemia? J Mol Cell Cardiol 13: 425–434, 1981PubMedCrossRefGoogle Scholar
  16. 16.
    Coker SJ, Parratt JR, Ledinghan I McA, Zeitlin IJ: Thromboxan and prostacyclin release from ischemic myocardium in relation to arrhythmias. Nature 291: 323–324, 1981PubMedCrossRefGoogle Scholar
  17. 17.
    Ahumada G, Sobel BE, Needleman P: Synthesis of prostaglandins by cultured rat heart myocytes and cardiac mesenchymal cells. J Mol Cell Cardiol 12:685–700, 1980PubMedCrossRefGoogle Scholar
  18. 18.
    Bolton HS, Chanderbhan R, Bryat RW, Bailey JM, Weglicki WB Vahouny GV: Prostaglandin synthesis by adult cardiac myocytes. Mol Cell Cardiol 12: 1287–1298, 1980CrossRefGoogle Scholar
  19. 19.
    Karmazyn M: Synthesis and release of cardiac eicosanoids with particular emphasis on ischemia and reperfusion. Can J Physiol Pharmacol 67:912–921, 1989PubMedCrossRefGoogle Scholar
  20. 20.
    Ferrari R, Cargnoni A, Ceconi C, Curello S, Belloli S, Albertini A, Visioli O: Protective effect of prostacyclin-mimetic on the ischemic-reperfused rabbit myocardium. J Mol Cell Cardiol 20: 1095–1106, 1988PubMedCrossRefGoogle Scholar
  21. 21.
    Ravingerova T, Tribulova N, Ziegelhoffer A, Styk J, Szekeres L: Suppression of reperfusion induced arrhythmias in the isolate rat heart: pretreatment with 7-oxo prostacyclin in vivo. Cardiovasc Res 27: 1051–1055, 1993PubMedCrossRefGoogle Scholar
  22. 22.
    Simpson PJ, Lucchesi BR: Myocardial ischemia: The potential therapeutic role of prostacyclin and its analogues. In R.J. Gryglewski and G. Stock (Eds). Springer-Verlag, Berlin/Heidelberg, 1988, pp 179–194Google Scholar
  23. 23.
    Parratt J: Endogenous myocardial protective (antiarrhythmic) substances. Cardiovasc Res 27: 693–702, 1993PubMedCrossRefGoogle Scholar
  24. 24.
    Schror K, Addicks K, Darius H, Ohlendorf R, Rosen P: PGI2 inhibits platelet activation and prevents myocardial damage by inhibition of catecholamine release from adrenergic nerve terminals. Evidence for cAMP as common denominator. Thromb Res 21:175–180, 1981PubMedCrossRefGoogle Scholar
  25. 25.
    Szekeres L, Szilvassy, Udvary E, Vegh A: 7-oxo-PGI2 induced late appearing and long-lasting electrophysiological changes in the heart in situ of the rabbit, guinea-pig, dog and cat. J Mol Cell Cardiol 21: 545–554,1989PubMedCrossRefGoogle Scholar
  26. 26.
    Liu GS, Stanley AW, Downey J: Cyclooxygenase products are not involved in the protection against myocardial infarction afforded by preconditioning in rabbit. Cyclooxygenase pathway’s involvement in preconditioning. Am J Cardiovasc Pathol 4: 157–164, 1992PubMedGoogle Scholar
  27. 27.
    Wainwright CL: Myocardial preconditioning as the heart’s self protecting response against the consequences of ischemia. Trends Pharmacol Sci 13: 90–93, 1992PubMedCrossRefGoogle Scholar
  28. 28.
    Fagbemi SO: The effect of aspirin, indomethacin and sodium meclofenamate on coronary artery ligation arrhythmias in anaesthetized rats. Eur J Pharmacol 97: 283–287, 1984PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Michael Arad
    • 1
    • 2
  • Tatiana Oxman
    • 1
    • 2
  • Ron Leor
    • 1
    • 2
  • Babeth Rabinowitz
    • 1
    • 2
  1. 1.Cardiac Metabolism Laboratory, Heart InstituteSheba Medical CenterTel HashomerIsrael
  2. 2.Sackler School of MedicineTel-Aviv UniversityTel AvivIsrael

Personalised recommendations